Annals of Indian Academy of Neurology is a premier open access journal dedicated to advancing the field of Neurology, serving as a vital resource for researchers, healthcare professionals, and students since its inception in 2006. Published by the esteemed Wolters Kluwer Medknow Publications, this journal has established itself within the academic community, boasting a Q3 quartile ranking in clinical neurology according to the 2023 category quartiles and a Scopus rank placing it in the 35th percentile among 400 comparable journals. With a focus on clinical advancements and research innovations in neurology, the journal aims to disseminate high-quality and impactful studies that address the complex challenges faced in the neurological landscape, particularly within the Indian context. The open access model ensures that the latest research is readily accessible to a global audience, thereby promoting collaboration and knowledge sharing within the neurosciences.

The International Journal of Breast Cancer is a premier academic platform dedicated to advancing the field of breast cancer research and treatment. Published by HINDAWI LTD, this journal embraces an Open Access model since 2011, ensuring that cutting-edge research is readily accessible to all, facilitating the dissemination of knowledge across the global scientific community. With its ISSN 2090-3170 and E-ISSN 2090-3189, the journal caters to a diverse audience comprising researchers, clinicians, and students engaged in oncology and pharmacology. The journal has consistently demonstrated its relevance, classified in the Q4 quartile for Cancer Research and the Q3 quartile for both Oncology and Pharmacology in the latest rankings. It currently ranks #151/272 in the Medicine & Pharmacology category and #232/404 in Medicine & Oncology according to Scopus, showcasing its adaptive role in an evolving field. Commencing in 2013 and continuing through to 2024, the journal is positioned to be an essential resource, addressing critical topics and fostering innovative solutions for breast cancer challenges.

Neurology Research International, published by HINDAWI LTD, is an esteemed open access journal that has been serving the neurology community since 2010. With its ISSN 2090-1852 and E-ISSN 2090-1860, this journal aims to foster knowledge dissemination and facilitate dialogue surrounding key issues in neurology and clinical neuroscience, making it a vital resource for researchers, clinicians, and students alike. It operates from the United States, with its administrative hub located in London, England. As of 2023, the journal has been positioned in the Q3 category for both neurology and clinical neurology, reflecting its commitment to advancing research within these critical fields. With a current Scopus rank of #216/400 in clinical neurology and a #113/192 in neuroscience, and a converged publication timeline from 2010 to 2024, Neurology Research International is dedicated to promoting high-quality research that addresses contemporary challenges and innovations in neurological science. By offering open access since its inception, it ensures that cutting-edge research is freely available, aligning with the global push towards accessible scientific communication.

The Journal of Movement Disorders, published by the Korean Movement Disorders Society, is a premier open access journal dedicated to advancing the field of neurology with a specific focus on movement disorders. Established in 2008 and indexed with ISSN 2005-940X and E-ISSN 2093-4939, this journal plays a vital role in disseminating high-quality research and clinical insights to a global audience. With an impressive Q2 ranking in both Neurology and Clinical Neurology categories for 2023, the journal continues to feature innovative research articles that contribute to better understanding and management of various movement disorders. Ranked 104th out of 400 in Clinical Neurology and 54th out of 192 in Neuroscience, the Journal of Movement Disorders offers an essential platform for researchers, healthcare professionals, and students alike, fostering collaboration and knowledge exchange in a rapidly evolving field.

NEUROCHEMISTRY INTERNATIONAL, published by Pergamon-Elsevier Science Ltd, offers a premier platform for researchers and professionals in the realms of cell biology and cellular and molecular neuroscience. Established in 1980 and continuing its passion for advancing the field, this esteemed journal enhances scientific collaboration with a notable 2023 Q2 ranking in both relevant categories, placing it among the top-tier publications in its discipline with a Scopus rank of 23/97 for Cellular and Molecular Neuroscience. With its focus on groundbreaking research, the journal provides a wealth of vital data and insights that drive forward our understanding of neurochemistry and its implications in health and disease. While not an Open Access journal, NEUROCHEMISTRY INTERNATIONAL is integral for professionals, academics, and students aiming to stay at the forefront of neurobiological research innovations, making significant contributions to both academia and clinical applications.

AIMS Neuroscience is an esteemed open-access journal published by the American Institute of Mathematical Sciences (AIMS), dedicated to advancing the field of neuroscience since its inception in 2014. With a robust ISSN of 2373-8006 and an E-ISSN of 2373-7972, this journal aims to provide a platform for innovative research and scholarly discourse that spans the diverse and dynamic landscape of the neuroscience discipline. As of 2023, it holds a respectable Q3 category ranking in the miscellaneous neuroscience field and ranks #65 out of 113 in general neuroscience according to Scopus, positioning it in the 42nd percentile for impact. AIMS Neuroscience encompasses a broad scope of topics, from neurobiology and cognitive neuroscience to computational models and neuroengineering, making it a vital resource for researchers, professionals, and students alike. The journal's commitment to open access ensures that cutting-edge research is freely available, fostering collaboration and knowledge sharing within the global neuroscience community.

Neurodegenerative Diseases, published by KARGER, is a prominent academic journal dedicated to advancing the field of neurology and neuroscience. With an ISSN of 1660-2854 and E-ISSN 1660-2862, this journal serves as a vital platform for researchers, professionals, and students engaged in the exploration of neurodegenerative disorders from various perspectives, including clinical applications and therapeutic interventions. Spanning two decades since its inception in 2004 and set to converge in 2024, it has steadily built a reputation within the academic community, achieving a commendable Q2 ranking in clinical neurology and Q3 in general neurology according to the 2023 category quartiles. The journal boasts an impressive Scopus rank of 114/400 (71st percentile) in clinical neurology and 58/192 (70th percentile) in neuroscience neurology. While not classified as open access, the publication provides critical insights into the latest research and developments, making it an essential resource for anyone dedicated to understanding and combating neurodegenerative diseases.

JOURNAL OF PSYCHIATRY & NEUROSCIENCE, published by the CMA-Canadian Medical Association, serves as a pivotal platform for disseminating cutting-edge research in the fields of psychiatry and neuroscience. This esteemed journal, indexed with the ISSN 1180-4882 and E-ISSN 1488-2434, focuses on advancing our understanding of mental health through meticulous peer-reviewed articles, reviews, and clinical studies. With an impressive impact within the research community, it has achieved notable rankings, including Q1 in both Medicine (miscellaneous) and Psychiatry and Mental Health, as well as Q2 in Biological Psychiatry as of 2023. The journal fosters critical dialogue among scholars and practitioners by offering insights into the complexities of brain function and mental disorders, making it a fundamental resource for healthcare professionals, researchers, and students alike. Although it operates under a subscription model, its rich content continues to inform and influence the advancement of mental health science, affirming its role in bridging the gap between research and clinical practice.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.

ASN Neuro is an esteemed academic journal published by Frontiers Media SA, focusing on critical advancements in the fields of neurology and neuroscience. Since its inception in 2009, it has established itself as an Open Access platform dedicated to fostering the dissemination of knowledge and research findings that address the complexities of the nervous system. With an impressive impact factor and consistently ranking in the top quartiles of its categories—Q1 in Neurology (clinical) and Q2 in Neuroscience (miscellaneous)—ASN Neuro is recognized for its high-quality publications that cater to the evolving challenges in clinical neurology and general neuroscience. Currently, it ranks 68th out of 400 journals in Clinical Neurology and 28th out of 113 in General Neuroscience, affirming its reputable position within the academic community. Researchers, professionals, and students alike are encouraged to contribute to and benefit from this impactful journal as it presents a unique opportunity to engage with cutting-edge research, innovative methodologies, and insightful reviews in the ever-evolving landscape of brain science.